Background: In many centres surgery is used as part of a combined modality approach to the treatment of inflammatory breast cancer (IBC). Nevertheless, its value is controversial given the high risk of metastatic relapse and poor overall prognosis. We have reviewed patients with true IBC prospectively treated at the Royal Marsden Hospital in chemotherapy trials to assess further the role of surgery as part of combined modality treatment.
Introduction
Inflammatory breast cancer (IBC) is an uncommon disease accounting for l%-4% of all breast cancers [1] . The characteristic pathological feature is malignant invasion of dermal lymphatics, but the classic clinical features of erythema and oedema are usually so obvious that skin biopsy is not mandatory for diagnosis [2] . Classified as a subset of locally advanced breast cancer (LABC), IBC has an aggressive natural history characterised by rapid tumour growth with the early development of distant metastatic disease, and hence has a worse prognosis than non-inflammatory LABC. Haagensen [3] demonstrated the inadequacy of surgery alone in the treatment of IBC with a mean survival of 19 months and a five-year survival rate of 3% in a group of 30 patients; results confirmed by other early studies [4] [5] [6] . Radical radiotherapy therefore became the treatment of choice. However, this also was shown to be largely ineffective with survival times of 11-33 months and five-year survival rates similar to the disappointing results achieved by surgery alone [1, 7, 8] . The combination of radiotherapy with surgery, while resulting in improved locoregional control [9] , did not lead to an improvement in survival when compared with either treatment given alone, reflecting the systemic nature of the disease [10] . An advance in the treatment of IBC came with the incorporation of chemotherapy (either as primary (neoadjuvant, induction) or as adjuvant therapy) as part of a multi-modality treatment approach. With chemotherapy patient outlook improved, with five-year survival figures of between 30%-50% in larger studies [11] .
Despite general consensus on the use of a multimodality approach with the inclusion of chemotherapy in the treatment of IBC, disagreement remains over the most appropriate form of loco-regional therapy, and in particular whether radiotherapy alone is sufficient or the combination of surgery plus radiotherapy is superior. In order to examine this issue, we have reviewed the locoregional treatment of all patients with true IBC defined prospectively in a series of chemotherapy trials carried out since 1986 at the Royal Marsden Hospital. In these studies local therapy was left to the discretion of the surgeons involved. Outcomes were compared between patients receiving radiotherapy alone following successful completion of primary chemotherapy and those undergoing surgery (either mastectomy or conservative surgery) plus radiotherapy. 
Patients and methods
modification was made to radiotherapy dose or schedule based on whether conservative surgery or no surgery was used. The decision on surgery was also often determined by clinician and patient preference, reflecting clinical uncertainty on this issue. In addition, there was a trend towards patients with a complete clinical response to chemotherapy being offered radiotherapy alone. The extent of surgery was determined by the surgeon involved, ranging from conservative resection to modified radical mastectomy, often with pedicle or free flap reconstruction.
Hormonal therapy with tamoxifen (20 mg/day for a period of 2-5 years as part of a separate trial) was given to patients who were either post-menopausal at the time of diagnosis or whose tumours were oestrogen receptor positive or unknown.
Statistical methods
Differences in the patient characteristics between the treatment groups were tested by the Mann-Whitney test (continuous variables), the x 2 test with Yates correction (categorical variables), or the Mann-Whitney test with trend (ordered categorical variables). All /"-values are two sided.
Response duration, time to progression, and overall survival curves were generated according to the Kaplan-Meier method and compared by means of the logrank test. The independent significance of the prognostic variables was assessed by means of a multivanate survival analysis using Cox's proportional hazards model A step-up procedure was used and variables were added to the model if the two-sided significance level was less than 0.05.
This was not a randomised trial and the choice of local therapy was partly based on prognostic factors. We have attempted to control for this bias by means of the multivariate analysis in which the effect of the local treatment was assessed after adjustment for all the other prognostic variables.
Patient population
Sixty-four consecutive patients with newly diagnosed untreated IBC were referred to the Breast Unit at the Royal Marsden Hospital, London between April 1986 and May 1998 and were prospectively entered into ongoing trials of primary chemotherapy. Although pathological confirmation of breast cancer was obtained in all cases, the diagnosis of IBC was clinically based and defined as a tumour of any size with diffuse brawny induration of the breast and inflammatory change. Patients with non-inflammatory locally advanced breast cancer were excluded. All patients were required to have a good performance status (World Health Organisation grade 0-2), and adequate renal, hepatic and bone marrow function.
Initial staging investigations included clinical examination with two-dimensional tumour measurement and clinical photography, breast imaging, full blood count, plasma biochemistry, liver function tests and chest X-ray. Imaging of other potential metastatic sites (e.g., liver, bone) was only performed if there was clinical or biochemical suspicion of disease.
Of the 64 patients, 49 received an anthracycline combination chemotherapy schedule (based upon either epirubicin, doxorubicin or mitoxantrone (for actual combinations see Table 1 ), and 15 received the conventional CMF (cyclophosphamide, methotrexate and 5-fluourouracil (5-FU)) schedule. All schedules were administered for a maximum of six cycles or until disease progression.
Following completion of chemotherapy schedule, patients went on to receive locoregional therapy as follows: all patients were offered radical radiotherapy to the breast and regional nodes unless this was refused or was deemed clinically inappropriate due to progressive disease elsewhere. In general radiotherapy was not given to the axilla following surgical axillary node resection. There was a variety of doses and schedules administered, reflecting both differing local practices, and changing radiotherapy practice over the study period. No
Results
Of the 64 patients receiving primary chemotherapy, 54 were suitable for study. The remaining 10 patients were excluded for a number of reasons: 5 had progressive disease during chemotherapy, 3 underwent surgery alone, and 2 had no loco-regional therapy at all. These five latter patients did not receive radiotherapy due either to patient refusal, or to the development of progressive metastatic disease after completion of chemotherapy but before loco-regional treatment could begin.
The demographics and treatment characteristics of these 54 patients are shown and compared in Table 1 . Thirty-five patients went on to have radical radiotherapy alone and nineteen had a combination of surgery and radiotherapy. As can be seen from the table, there were some differences between the two groups. In particular, the radiotherapy-alone group had significantly more clinical nodal disease. With regards chemotherapy, there was no significant difference in terms of infusional regimens vs. bolus regimens (P -0.7), or anthracycline regimens vs. CMF (P -0.3).
Locoregional treatment administered
The type and sequence of loco-regional therapy given is shown in Table 2 . In the radiotherapy-alone group all patients had their breast and axilla irradiated, and the The five patients receiving radiotherapy prior to surgery also had radiation treatment to the axilla, doses ranging from 42.9 to 60 Gy.
majority also had their ipsilateral supraclavicular fossa treated. The median radiotherapy dose to the breast/ chest wall was 60 Gy (range 54-76). In the group of 19 patients undergoing both surgery and radiotherapy, 14 had their surgery first with 8 undergoing a mastectomy and 6 conservative surgery. These six had achieved either a good partial response to chemotherapy (four patients) or a complete clinical response (two patients). This was followed by chest wall radiotherapy (median dose 50 Gy, range 40-60). The other five patients had their radiotherapy treatment first (including breast, axilla, and supraclavicular fossa, median dose 59.2 Gy, range 56-60), before going on to have a mastectomy.
Chemotherapy response, radiotherapy response, time to progression and survival
The clinical tumour responses to chemotherapy and then to radiotherapy are shown in Table 3 . The overall chemotherapy response rate for the 35 patients later receiving radiotherapy alone was 89% (95% confidence interval (95% CI): 78%-99%) compared to an overall response rate of 74% (95% Cl: 54%-93%) in the patients later treated with both surgery and radiotherapy. A clinical complete response (cCR) was seen in 15 patients (43%, 95% CI: 27%-59%) in the radiotherapy-alone group. This was significantly greater than seen in the patients later receiving both surgery and radiotherapy where four patients (21%, 95% CI: 3%-39%) achieved a cCR (P = 0.07).
Of the 20 patients in the radiotherapy-alone group who had either a clinical partial response (cPR) or stable disease (SD) following primary chemotherapy, 9 had a response to radiotherapy treatment. Seven patients had their disease response converted from a cPR to a cCR, and two patients with SD achieved a cCR and a cPR, respectively. Five patients in the surgery plus radiotherapy group had radiotherapy treatment first, allowing a response to radiotherapy to be measured. Of these five patients, two responded: one achieving a cCR (following a cPR to chemotherapy), and one a cPR (following SD to chemotherapy).
The median duration of follow up of patients still alive at the time of analysis was 43 months (range 12-131 months) for patients in the radiotherapy-alone group, and 26 months (range 11-75 months) for patients in the surgery plus radiotherapy group. The median time to disease progression for patients receiving radiotherapy alone was 16 months (range 5-131+), while that for patients receiving surgery and radiotherapy was 20 months (range 5-75+) months (P -0.5, Figure 1 ). The median overall survival for the radiotherapy-alone patients was 35 months (range 7-131+ months),and for surgery plus radiotherapy it was also 35 months (range 9-75+ months, P -0.5, Figure 2 ). The five-year diseasefree survival and five-year overall survival figures for patients treated with radiotherapy-alone were 24% and 38%, respectively, compared with 9% and 15%, respectively, for surgery plus radiotherapy treated patients.
Multivariate analysis

Progression-free survival
In univariate analysis, non-response to chemotherapy (P = 0.01), higher nodal stage (P = 0.02), and younger age (less than 50, P = 0.05) were all poor prognostic factors for progression-free survival (data not shown). In multivariate analysis, menopausal status had an additional effect, with post-menopausal women having a poorer progression free survival. Locoregional therapy had no effect (Table 4) . • VI ' Years since chemotherapy 
Overall survival
In univariate analysis, higher clinical nodal stage (P -0.02) and younger age (less than 50, P = 0.06) were poor prognostic factors for survival. After adjusting for these two factors, response to chemotherapy and menopausal status also had an effect upon survival, with non-responders and post-menopausal women having a poorer prognosis. The type of loco-regional therapy given had no effect ( Table 5 ). The results for age and menopausal status appear to conflict, but there were two post-and three peri-menopausal patients under the age of 50, all of who have died (4 within 2 years from treatment). Conversely, there were one pre-and one perimenopausal women aged > 50 years. Both of these remain alive at three and at five years follow-up.
Site of first relapse
In the radiotherapy-alone group, 24 of 35 patients (69%) have relapsed since completing their loco-regional therapy (Table 6 ). Thirteen patients (37%) developed distant metastases as the site of first relapse, while eleven patients (31%) first relapsed locally in either the breast or the axilla. Three of these eleven relapsed with simultaneous local and metastatic disease. A further 1 patient developed a local relapse after first having developed metastatic disease, resulting in a total local relapse rate of 12 of 35 (34%). These local relapses occurred at a median of 8 months (range 3-14) post commencement of loco-regional therapy, and only one patient presented with uncontrolled local disease. The local relapses were treated in a variety of ways: three patients underwent mastectomy, four patients received chemotherapy, four patients had endocrine therapy, and one patient refused all further treatment.
In the group treated with surgery and radiotherapy, 15 of 19 patients (79%) have relapsed since completion of their loco-regional therapy, with 9 patients (42%) relapsing first at a distant site ( Table 6 ). The other six patients (32%) relapsed first locally, either in the chest wall/breast or in the axilla; two of these were concurrent local and metastatic disease. Four of the local relapses occurred in the six patients who had initially undergone breast conserving surgery, while two occurred in the group of thirteen patients who had initially under-gone a mastectomy. A further 2 patients developed local relapse after first having developed metastatic disease, resulting in a total local relapse rate of 8 of 19 (42%). These local relapses occurred at a median of 12 months (range 1-47) post commencement of loco-regional therapy, and there were no cases of uncontrolled local disease. At relapse, one patient had a completion mastectomy, one patient an axillary clearance, four patients received endocrine therapy and one received chemotherapy. Data was unavailable in one patient.
In the radiotherapy-alone group, the median duration from day 1 of the last cycle of chemotherapy to the initiation of radiotherapy was 35.5 days (range 14-83 days), while in the surgery plus radiotherapy group, the median duration to the initiation of the first loco-regional therapy was 36 days (range 21-90 days).
Toxicity
Severe toxicity (WHO grade 3-4) was relatively uncommon in either treatment group, either secondary to chemotherapy or to the loco-regional treatment. The major chemotherapy-related toxicities were alopecia, lethargy, stomatitis, and neutropaenia. Apart from a slightly increased incidence of neutropaenia in the surgery plus radiotherapy group, there was no significant differences between the two groups (data not shown). The major radiation-related toxicity was skin erythema and discolouration. There were no long-term radiation toxicities observed, although this may be secondary to the fact that the majority of patients died within five years of diagnosis and treatment. Surgery was generally well tolerated. There were no treatment related deaths in either group.
Discussion
The administration of systemic chemotherapy has been a useful therapeutic advance in the treatment of IBC, resulting in an improvement in five-year survival rates from less than 5% to up to 30%-50% [10] . Effective local tumour control nevertheless remains an important component of treatment, but the best modality is controversial. There is general agreement, although not universal [12] that radiotherapy is a necessary component. Pathological examination of the amount of residual tumour following induction chemotherapy shows that significant numbers of patients have extensive residual disease, often greater than 5 cm 3 in size [13, 14] , and 1 study found that of 21 patients with IBC treated with primary chemotherapy and then undergoing a modified radical mastectomy, 8 had an incomplete resection due to muscle infiltration by tumour cells [15] . This suggests that radiotherapy is essential to attempt to achieve adequate local disease elimination.
The role of surgery in addition to chemotherapy and radiotherapy is more controversial. Theoretically, combined radiotherapy and surgery should achieve maximum local control, and if surgery precedes the radiotherapy, then a lower dose of chest wall radiotherapy should be required with subsequent lower risk of longterm radiotherapy toxicity. In addition, surgery after chemotherapy provides prognostic information regarding local control [16] and disease free survival [17] . On the other hand, IBC is fundamentally a systemic disease and the majority of patients still die of systemic metastases despite the advent of chemotherapy; in these circumstances, aggressive dual modality loco-regional treatment may be unnecessary and inappropriate, both from a toxicity and a quality of life point of view. Somewhat surprisingly, there have been few randomised trials of multimodality therapy attempting to answer this issue of optimal loco-regional disease control. De Lena et al. [17] published the results of a randomised study comparing chemotherapy followed by radiotherapy or mastectomy in 132 patients with locally advanced breast cancer. Results showed an identical overall response rate of 75%, with no significant difference between the groups in terms of median duration of response, pattern of treatment failure and four-year total survival. Unfortunately, there were no patients with IBC included in the study.
Perloffet al. [18] randomised stage III breast cancer patients to either surgery or to radiotherapy following three cycles of induction chemotherapy; further chemotherapy was given post local treatment. In 91 randomised patients, there were no statistically significant differences between the 2 groups in terms of disease control and median overall survival. Local recurrence as the site of first relapse was slightly more common in the radiotherapy arm, 55% vs. 42% (P = 0.43). Only 10 of the randomised patients actually had IBC. Table 7 . Non randomised studies and retrospective reviews of effect of locoregional therapy on the outcome of 1BC.
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Perez [9] Atta-Sobal [20] Pierce [21] Brun [22] Schafer [15] Koh [13] Chevallier [23] Ptno. Finally, Mourali et al. [19] presented a study of 83 patients with IBC treated with induction chemotherapy followed by randomisation to either radiotherapy alone or surgery alone. Sixty-eight patients were actually randomised and fifty-seven successfully completed both chemotherapy and loco-regional therapy. The results showed a trend for improved disease-free interval for patients in the radiotherapy arm, but this improvement was not significant. No data on differences in local recurrence rates were given.
In addition to these randomised studies, there have been a number of non-randomised studies, many of them retrospective single-institution reviews. As shown in Table 7 the studies show no consistent pattern [9, 13, 15, [20] [21] [22] [23] . Perez et al. [9] found a significantly higher local failure rate in patients treated with chemotherapy plus radiotherapy versus those treated with chemotherapy, surgery and radiotherapy (63% vs. 21%), and a similar magnitude of benefit was seen on five-year DFS and OS. Interestingly, they found no difference in the percentage of patients suffering major toxicities when the two groups were compared. Conversely, similar to the findings of our study, a number of papers have reported no benefit of adding surgery to radiotherapy following primary chemotherapy in terms of disease-free survival, overall survival or local recurrence rates. The results of our study, however, may have been influenced by a number of potential biases. In particular, patients with a complete clinical response to primary chemotherapy were encouraged to have radiotherapy alone, resulting in a higher percentage of these patients in this group (43% vs. 21%) compared with the surgery plus radiotherapy group. This may have improved the results for the radiotherapy-alone patients, as there have been a number of studies reporting a relationship between chemotherapy response and subsequent overall survival [13, 16, 24] . On the other hand, the radiotherapy-alone group included a higher percentage of patients with clinically palpable nodal disease, a factor one could expect to potentially worsen the outlook for this group. To allow for these differences, a multivariate analysis was performed for both progression-free and overall survival, and for both outcomes there was no significant effect of the type of loco-regional treatment delivered. In addition, surgery did not appear to impact upon the frequency of local recurrence with the surgery plus radiotherapy group having essentially the same local recurrence rate as the radiotherapy-alone group (42% vs. 34%). These local recurrences occurred within approximately the same time span in each group and patients in the radiotherapyalone group did not appear to suffer from an unacceptable incidence of uncontrolled local relapse. The management of local relapse was also similar between the two groups.
In conclusion, the optimal approach to loco-regional therapy in IBC remains unclear. Our data question the role of surgery and justify the need for a prospective randomised trial comparing induction chemotherapyradiotherapy versus chemotherapy-surgery-radiotherapy. Even so, the major goal in the treatment of IBC must still be more effective systemic therapies.
